RecruitingNot ApplicableNCT06433063
Effect of Hypoxia on FMISO PET to Response to Lu-177 PSMA Treatment
Effect of 18F-Fluoromisonidazole (18F-FMISO) PET Imaging on Evaluation of Hypoxia Before Lu-177 PSMA Treatment for Prostate Cancer
Sponsor
Cigdem Soydal
Enrollment
30 participants
Start Date
Feb 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
It is aimed to evaluate hypoxia before Lu-177 PSMA treatment in prostate cancer and to show its effect on treatment success with 18F-FMISO PET imaging, which allows in-vivo evaluation and quantification of tumor hypoxia, which is known to be one of the factors affecting radiotherapy resistance.
Eligibility
Sex: MALEMin Age: 18 Years
Inclusion Criteria2
- over 18 years old
- Patients diagnosed with prostate cancer who were referred to our clinic for Lu-177 PSMA treatment and were found suitable for treatment
Exclusion Criteria3
- Has a life expectancy of less than 3 months
- ECOG\>2
- contraindication for radionuclide treatment with Lu-177 PSMA
Interventions
DIAGNOSTIC_TESTF-MISO PET
Evaluation of tumor hypoxia with F-MISO PET
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06433063
Related Trials
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
NCT070829206 locations
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
NCT056166501 location
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
NCT0605683027 locations
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
NCT073198713 locations
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737274 locations